Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
IL-5 antagonist
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA gptkb:United_States |
| gptkbp:brand |
gptkb:Nucala
|
| gptkbp:class |
gptkb:drug
|
| gptkbp:clinical_trial |
Phase III
add-on therapy |
| gptkbp:contraindication |
hypersensitivity to mepolizumab
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
gptkb:software_framework
|
| gptkbp:financial_performance |
24 hours at room temperature
|
| gptkbp:frequency |
once every 4 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
mepolizumab
|
| gptkbp:indication |
severe asthma
chronic rhinosinusitis with nasal polyps eosinophilic asthma |
| gptkbp:ingredients |
C_634 H_988 N_168 O_198 S_4
|
| gptkbp:invention |
2025
patented |
| gptkbp:is_available_on |
auto-injector
pre-filled syringe |
| gptkbp:is_monitored_by |
eosinophil counts
|
| gptkbp:is_used_for |
gptkb:eosinophilic_granulomatosis_with_polyangiitis
gptkb:asthma hypereosinophilia |
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:pharmacokinetics |
half-life of approximately 20 days
|
| gptkbp:provides_information_on |
recommended for severe asthma
recommended for chronic rhinosinusitis with nasal polyps recommended for eosinophilic granulomatosis with polyangiitis |
| gptkbp:research_areas |
asthma treatment
eosinophilic disorders |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
headache thromboembolic events back pain injection site reactions anaphylaxis serious infections nasopharyngitis |
| gptkbp:storage |
2 to 8 ° C
|
| gptkbp:targets |
IL-5
|
| gptkbp:weight |
146 k Da
|
| gptkbp:bfsParent |
gptkb:Nucala
gptkb:interleukin-5 |
| gptkbp:bfsLayer |
5
|